Fresenius (FRE) Q1 2025 earnings summary

Executive summary

• Q1 2025 delivered strong organic revenue and double-digit EPS growth, driven by robust performance at Kabi and Helios, and supported by operational momentum and lower interest expenses.

• Strategic transformation advanced with the exit from Vamed and reduction of the FMC stake, enhancing balance sheet flexibility and capital allocation.

• Leverage ratio improved to 3.0x, within the tightened target range, reflecting ongoing deleveraging efforts.

• Focus remains on scaling core platforms: specialized biopharma, targeted medtech, and holistic care provision.

• Helios Performance Programme delivered on schedule, supporting profitability.

Financial highlights

• Group organic revenue grew 7% year-over-year to €5.6bn; EBIT up 4% to €654m at constant currency.

• Core EPS increased 12–14% in Q1, reflecting operational leverage and lower interest expenses.

• Group EBIT margin at 11.6%, with Kabi at 16.8% and Helios at 9.8%.

• Free cash flow increased by nearly €2.1 billion over the last 12 months, driven by working capital and CapEx discipline.

• Net income before special items rose 14% to €490 million; reported net income was €229 million, impacted by special items.

Outlook and guidance

• Full-year 2025 guidance confirmed: organic revenue growth of 4–7% and EBIT growth of 3–7% at constant currency.

• Kabi expects mid- to high-single-digit organic revenue growth and EBIT margin of 16–16.5%; Helios targets EBIT margin around 10%.

• Interest expenses for 2025 expected at €370–390 million, down from prior guidance.

• Deleveraging remains a priority, with net debt/EBITDA target corridor set at 2.5–3.0x by year-end.

• Guidance reflects ongoing macroeconomic and geopolitical uncertainties.